239 PATTERNS OF CARE FOR HYPOMETHYLATING AGENTS (HMAS) IN MDS PATIENTS IN THE US: A DISTURBING LACK OF OPTIMAL TREATMENT TRANSLATES TO A RECIPE FOR FAILURE

Autor: Demakos, E.P., Silverman, L.R., Lawrence, M.E., McKearn, T.J., Megaffin, S., Petrone, M.E.

Publikováno v: In Leukemia Research April 2015 39 Supplement 1:S119-S119

203 MDS CONCEPTUAL FRAMEWORK IDENTIFIES UNMET NEED FOR HMA-UNRESPONSIVE AND TRANSPLANT-INELIGIBLE PATIENTS

Autor: Bentley, T., Broder, M., Megaffin, S., Petrone, M., McKearn, T., Kurtin, S., Cogle, C.

Publikováno v: In Leukemia Research April 2015 39 Supplement 1:S101-S101

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

Autor: Cogle CR; Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA christopher.cogle@medicine.ufl.edu., Kurtin SE; University of Arizona, Tucson, Arizona, USA., Bentley TG; Partnership for Health Analytic Research, LLC, Beverly Hills, California, USA., Broder MS; Partnership for Health Analytic Research, LLC, Beverly Hills, California, USA., Chang E; Partnership for Health Analytic Research, LLC, Beverly Hills, California, USA., Megaffin S; Churchill Pharmaceuticals, LLC, King of Prussia, Pennsylvania, USA., Fruchtman S; Onconova Therapeutics, Inc., Newtown, Pennsylvania, USA., Petrone ME; Onconova Therapeutics, Inc., Newtown, Pennsylvania, USA., Mukherjee S; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA.

Publikováno v: The oncologist [Oncologist] 2017 Apr; Vol. 22 (4), pp. 379-385. Date of Electronic Publication: 2017 Mar 10.

Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.

Autor: Cogle CR; a Division of Hematology and Oncology, Department of Medicine, College of Medicine , University of Florida , Gainesville , FL , USA., Ortendahl JD; b Partnership for Health Analytic Research, LLC , Beverly Drive , Beverly Hills , CA 90212 , USA., Bentley TG; b Partnership for Health Analytic Research, LLC , Beverly Drive , Beverly Hills , CA 90212 , USA., Anene AM; b Partnership for Health Analytic Research, LLC , Beverly Drive , Beverly Hills , CA 90212 , USA., Megaffin S; c Onconova Therapeutics, Inc , Newtown , PA , USA.; d Churchill Pharmaceuticals, LLC , King of Prussia , PA , USA., McKearn TJ; c Onconova Therapeutics, Inc , Newtown , PA , USA., Petrone ME; c Onconova Therapeutics, Inc , Newtown , PA , USA., Mukherjee S; e Department of Hematology and Medical Oncology , Cleveland Clinic Taussig Cancer Institute , Cleveland , OH , USA.

Publikováno v: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2016; Vol. 16 (2), pp. 275-84. Date of Electronic Publication: 2015 Nov 20.

Real‐world study of the use of azacitidine in myelodysplasia in Australia.

Autor: Enjeti, Anoop, Ashraf, Asma, Caillet, Vincent, Alam, Arif, Silar, Jonathan, Keer, Harold, Castaldi, Francesco, Paine, Taleisha

Publikováno v: EJHaem; Jun2024, Vol. 5 Issue 3, p527-534, 8p